Evaluation of Retinal Changes in Progressive Supranuclear Palsy and Parkinson Disease

被引:17
|
作者
Sevim, Duygu Gulmez [1 ]
Unlu, Metin [1 ]
Gultekin, Murat [2 ]
Karaca, Cagatay [1 ]
Mirza, Meral [2 ]
Mirza, Galip Ertugrul [1 ]
机构
[1] Erciyes Univ, Fac Med, Dept Ophthalmol, TR-38039 Kayseri, Turkey
[2] Erciyes Univ, Fac Med, Dept Neurol, Kayseri, Turkey
关键词
SEVERITY; ASSOCIATION; LEVODOPA;
D O I
10.1097/WNO.0000000000000591
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Differentiating Parkinson disease (PD) from progressive supranuclear palsy (PSP) can be challenging early in the clinical course. The aim of our study was to see if specific retinal changes could serve as a distinguishing feature. Methods: We used spectral domain optical coherence tomography (SD-OCT) with automatic segmentation to measure peripapillary nerve fiber layer thickness and the thickness and volume of retinal layers at the macula. Results: Thicknesses of superior peripapillary retinal nerve fiber layer (pRNFL), macular ganglion cell layer, inner plexiform layer, inner nuclear layer, and macular volume were more affected in PSP compared with PD (P < 0.05). Thicker inferotemporal pRNFL and lower macular volume were detected in levodopa users compared with nonusers in patients with PD. Conclusions: PD and PSP are associated with distinct changes in retinal morphology, which can be assessed with SD-OCT. (C) 2017 by North American Neuro-Ophthalmology Society
引用
收藏
页码:151 / 155
页数:5
相关论文
共 50 条
  • [21] OCULOMOTOR ABNORMALITIES IN PATIENTS WITH PARKINSON'S DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY
    Kocoglu, K.
    Boz, H. Eraslan
    Akkoyun, M.
    Colakoglu, B. Donmez
    Cakmur, R.
    Akdal, G.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E40 - E40
  • [22] Co-occurrence of Parkinson's disease with progressive supranuclear palsy
    Alexander R. Judkins
    Mark S. Forman
    Kunihiro Uryu
    David A. Hinkle
    Arthur K. Asbury
    Virginia M.-Y. Lee
    John Q. Trojanowski
    Acta Neuropathologica, 2002, 103 : 526 - 530
  • [23] Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease
    Aarsland, D
    Litvan, I
    Larsen, JP
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2001, 13 (01) : 42 - 49
  • [24] Functional and macrostructural anatomy of progressive supranuclear palsy and Parkinson's disease
    Burciu, R. G.
    Ofori, E.
    Snyder, A. F.
    Planetta, P. J.
    Okun, M. S.
    McFarland, N. R.
    Vaillancourt, D. E.
    MOVEMENT DISORDERS, 2014, 29 : S68 - S68
  • [25] Evaluation of supranuclear palsy rating scale in patients with progressive supranuclear palsy
    Rai, N. K.
    Goyal, V.
    Shukla, G.
    Kumar, N.
    Shrivastava, A. K.
    Behari, M.
    MOVEMENT DISORDERS, 2013, 28 : S283 - S285
  • [26] Minimal Cytological Changes of Progressive Supranuclear Palsy Type in Clinically Possible Progressive Supranuclear Palsy
    Toru, S.
    Uchihara, T.
    Akashi, T.
    Kobayashi, T.
    EUROPEAN NEUROLOGY, 2010, 63 (02) : 122 - 125
  • [27] Evaluation of supranuclear palsy rating scale in patients with progressive supranuclear palsy
    Rai, N. K.
    Goyal, V.
    Kumar, N.
    Shukla, G.
    Srivastava, A. K.
    Behari, M.
    MOVEMENT DISORDERS, 2012, 27 : S390 - S391
  • [28] Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis
    Kanel, Prabesh
    Spears, C. Chauncey
    Roytman, Stiven
    Koeppe, Robert A.
    Frey, Kirk A.
    Scott, Peter J. H.
    Albin, Roger L.
    Bohnen, Nicolaas, I
    JOURNAL OF NEURAL TRANSMISSION, 2022, 129 (12) : 1469 - 1479
  • [29] Differential cholinergic systems’ changes in progressive supranuclear palsy versus Parkinson’s disease: an exploratory analysis
    Prabesh Kanel
    C. Chauncey Spears
    Stiven Roytman
    Robert A. Koeppe
    Kirk A. Frey
    Peter J. H. Scott
    Roger L. Albin
    Nicolaas I. Bohnen
    Journal of Neural Transmission, 2022, 129 : 1469 - 1479
  • [30] MRI evaluation of Progressive Supranuclear Palsy
    Kamada, M.
    MOVEMENT DISORDERS, 2020, 35 : S504 - S505